The Lung Cancer Research Foundation and Free to Breathe announced a merger to make an even greater impact on closing the funding gap for lung cancer research. The New York State Attorney General approved the required merger documentation on Sept. 30.
In a unanimous vote, the FDA Oncologic Drugs Advisory Committee advised the agency to accept the metric of “minimal residual disease,” or MRD, as a basis for accelerated approvals of therapies in all settings of multiple myeloma.
